Multiple Sclerosis Market in US 2025-2029

Best Price Guarantee	Length	Publisher	Published Date	SKU
from $2,500	139 Pages	TechNavio	December, 2024	INF19463013

Best Price Guarantee
Price	from $2,500
Length	139 Pages
Publisher	TechNavio
Published Date	December, 2024
SKU	INF19463013

Multiple Sclerosis Market In US 2025-2029

The multiple sclerosis market in us is forecasted to grow by USD 4.99 bn during 2024-2029, accelerating at a CAGR of 6.2% during the forecast period. The report on the multiple sclerosis market in us provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.

The report offers an up-to-date analysis regarding the current market scenario, the latest trends and drivers, and the overall market environment. The market is driven by strong pipeline of vendors, rising prevalence of multiple sclerosis, and disease-modifying therapies.

Technavio's multiple sclerosis market in us is segmented as below:

By Route Of Administration

Parenteral
Oral

By Type

Biologics
Small molecules

By Geographical Landscape

North America

This study identifies the rising strategic alliances and partnerships among vendors as one of the prime reasons driving the multiple sclerosis market in us growth during the next few years. Also, rising product approval and stem cell treatment for multiple sclerosis will lead to sizable demand in the market.

The report on the multiple sclerosis market in us covers the following areas:

Multiple Sclerosis Market in US sizing
Multiple Sclerosis Market in US forecast
Multiple Sclerosis Market in US industry analysis

The robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading multiple sclerosis market in us vendors that include AB Science SA, Astellas Pharma Inc., Bayer AG, Biogen Inc., Bristol Myers Squibb Co., F. Hoffmann La Roche Ltd., GeNeuro SA, Glenmark Pharmaceuticals Ltd., Inno BioScience LLC, Johnson and Johnson Inc., Mapi Pharma Ltd., MediciNova Inc., Merck KGaA, Novartis AG, Opexa Therapeutics Inc., Pfizer Inc., Sanofi SA, Sobel Network Shipping Co. Inc., Teva Pharmaceutical Industries Ltd., and Viatris Inc.. Also, the multiple sclerosis market in us analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage all forthcoming growth opportunities.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors.

The publisher presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive primary and secondary research. The market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast accurate market growth.

1 Executive Summary: 1.1 Market overview; Executive Summary - Chart on Market Overview; Executive Summary - Data Table on Market Overview; Executive Summary - Chart on Country Market Characteristics; Executive Summary - Chart on Market Segmentation by Route of Administration; Executive Summary - Chart on Market Segmentation by Type; Executive Summary - Chart on Company Market Positioning
2 Technavio Analysis: 2.1 Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria; Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria; 2.2 Criticality of inputs and Factors of differentiation; Overview on criticality of inputs and factors of differentiation; 2.3 Factors of disruption; Overview on factors of disruption; 2.4 Impact of drivers and challenges; Impact of drivers and challenges in 2024 and 2029
3 Market Landscape: 3.1 Market ecosystem; Parent Market; Data Table on - Parent Market; 3.2 Market characteristics; Market characteristics analysis; 3.3 Value chain analysis; Value chain analysis
4 Market Sizing: 4.1 Market definition; Offerings of companies included in the market definition; 4.2 Market segment analysis; Market segments; 4.3 Market size 2024; 4.4 Market outlook: Forecast for 2024-2029; Chart on US - Market size and forecast 2024-2029 ($ billion); Data Table on US - Market size and forecast 2024-2029 ($ billion); Chart on US: Year-over-year growth 2024-2029 (%); Data Table on US: Year-over-year growth 2024-2029 (%)
5 Historic Market Size: 5.1 Multiple Sclerosis Market in US 2019 - 2023; Historic Market Size - Data Table on Multiple Sclerosis Market in US 2019 - 2023 ($ billion); 5.2 Route of Administration segment analysis 2019 - 2023; Historic Market Size - Route of Administration Segment 2019 - 2023 ($ billion); 5.3 Type segment analysis 2019 - 2023; Historic Market Size - Type Segment 2019 - 2023 ($ billion)
6 Qualitative Analysis: 6.1 Impact of AI on Multiple Sclerosis Market in US
7 Five Forces Analysis: 7.1 Five forces summary; Five forces analysis - Comparison between 2024 and 2029; 7.2 Bargaining power of buyers; Bargaining power of buyers - Impact of key factors 2024 and 2029; 7.3 Bargaining power of suppliers; Bargaining power of suppliers - Impact of key factors in 2024 and 2029; 7.4 Threat of new entrants; Threat of new entrants - Impact of key factors in 2024 and 2029; 7.5 Threat of substitutes; Threat of substitutes - Impact of key factors in 2024 and 2029; 7.6 Threat of rivalry; Threat of rivalry - Impact of key factors in 2024 and 2029; 7.7 Market condition; Chart on Market condition - Five forces 2024 and 2029
8 Market Segmentation by Route of Administration: 8.1 Market segments; Chart on Route of Administration - Market share 2024-2029 (%); Data Table on Route of Administration - Market share 2024-2029 (%); 8.2 Comparison by Route of Administration; Chart on Comparison by Route of Administration; Data Table on Comparison by Route of Administration; 8.3 Parenteral - Market size and forecast 2024-2029; Chart on Parenteral - Market size and forecast 2024-2029 ($ billion); Data Table on Parenteral - Market size and forecast 2024-2029 ($ billion); Chart on Parenteral - Year-over-year growth 2024-2029 (%); Data Table on Parenteral - Year-over-year growth 2024-2029 (%); 8.4 Oral - Market size and forecast 2024-2029; Chart on Oral - Market size and forecast 2024-2029 ($ billion); Data Table on Oral - Market size and forecast 2024-2029 ($ billion); Chart on Oral - Year-over-year growth 2024-2029 (%); Data Table on Oral - Year-over-year growth 2024-2029 (%); 8.5 Market opportunity by Route of Administration; Market opportunity by Route of Administration ($ billion); Data Table on Market opportunity by Route of Administration ($ billion)
9 Market Segmentation by Type: 9.1 Market segments; Chart on Type - Market share 2024-2029 (%); Data Table on Type - Market share 2024-2029 (%); 9.2 Comparison by Type; Chart on Comparison by Type; Data Table on Comparison by Type; 9.3 Biologics - Market size and forecast 2024-2029; Chart on Biologics - Market size and forecast 2024-2029 ($ billion); Data Table on Biologics - Market size and forecast 2024-2029 ($ billion); Chart on Biologics - Year-over-year growth 2024-2029 (%); Data Table on Biologics - Year-over-year growth 2024-2029 (%); 9.4 Small molecules - Market size and forecast 2024-2029; Chart on Small molecules - Market size and forecast 2024-2029 ($ billion); Data Table on Small molecules - Market size and forecast 2024-2029 ($ billion); Chart on Small molecules - Year-over-year growth 2024-2029 (%); Data Table on Small molecules - Year-over-year growth 2024-2029 (%); 9.5 Market opportunity by Type; Market opportunity by Type ($ billion); Data Table on Market opportunity by Type ($ billion)
10 Customer Landscape: 10.1 Customer landscape overview; Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria
11 Drivers, Challenges, and Opportunity/Restraints: 11.1 Market drivers; 11.2 Market challenges; 11.3 Impact of drivers and challenges; Impact of drivers and challenges in 2024 and 2029; 11.4 Market opportunities/restraints
12 Competitive Landscape: 12.1 Overview; 12.2 Competitive Landscape; Overview on criticality of inputs and factors of differentiation; 12.3 Landscape disruption; Overview on factors of disruption; 12.4 Industry risks; Impact of key risks on business
13 Competitive Analysis: 13.1 Companies profiled; Companies covered; 13.2 Company ranking index; Company ranking index; 13.3 Market positioning of companies; Matrix on companies position and classification; 13.4 Bayer AG; Bayer AG - Overview; Bayer AG - Business segments; Bayer AG - Key news; Bayer AG - Key offerings; Bayer AG - Segment focus; SWOT; 13.5 Biogen Inc.; Biogen Inc. - Overview; Biogen Inc. - Product / Service; Biogen Inc. - Key news; Biogen Inc. - Key offerings; SWOT; 13.6 Bristol Myers Squibb Co.; Bristol Myers Squibb Co. - Overview; Bristol Myers Squibb Co. - Product / Service; Bristol Myers Squibb Co. - Key news; Bristol Myers Squibb Co. - Key offerings; SWOT; 13.7 F. Hoffmann La Roche Ltd.; F. Hoffmann La Roche Ltd. - Overview; F. Hoffmann La Roche Ltd. - Business segments; F. Hoffmann La Roche Ltd. - Key news; F. Hoffmann La Roche Ltd. - Key offerings; F. Hoffmann La Roche Ltd. - Segment focus; SWOT; 13.8 Johnson and Johnson Inc.; Johnson and Johnson Inc. - Overview; Johnson and Johnson Inc. - Business segments; Johnson and Johnson Inc. - Key news; Johnson and Johnson Inc. - Key offerings; Johnson and Johnson Inc. - Segment focus; SWOT; 13.9 Novartis AG; Novartis AG - Overview; Novartis AG - Business segments; Novartis AG - Key news; Novartis AG - Key offerings; Novartis AG - Segment focus; SWOT; 13.10 Pfizer Inc.; Pfizer Inc. - Overview; Pfizer Inc. - Product / Service; Pfizer Inc. - Key news; Pfizer Inc. - Key offerings; SWOT; 13.11 Sanofi SA; Sanofi SA - Overview; Sanofi SA - Business segments; Sanofi SA - Key news; Sanofi SA - Key offerings; Sanofi SA - Segment focus; SWOT; 13.12 Teva Pharmaceutical Industries Ltd.; Teva Pharmaceutical Industries Ltd. - Overview; Teva Pharmaceutical Industries Ltd. - Business segments; Teva Pharmaceutical Industries Ltd. - Key news; Teva Pharmaceutical Industries Ltd. - Key offerings; Teva Pharmaceutical Industries Ltd. - Segment focus; SWOT; 13.13 Viatris Inc.; Viatris Inc. - Overview; Viatris Inc. - Business segments; Viatris Inc. - Key news; Viatris Inc. - Key offerings; Viatris Inc. - Segment focus; SWOT
14 Appendix: 14.1 Scope of the report; 14.2 Inclusions and exclusions checklist; Inclusions checklist; Exclusions checklist; 14.3 Currency conversion rates for US$; Currency conversion rates for US$; 14.4 Research methodology; Research methodology; 14.5 Data procurement; Information sources; 14.6 Data validation; Data validation; 14.7 Validation techniques employed for market sizing; Validation techniques employed for market sizing; 14.8 Data synthesis; Data synthesis; 14.9 360 degree market analysis; 360 degree market analysis; 14.10 List of abbreviations; List of abbreviations
Exhibits:: Exhibits1: Executive Summary - Chart on Market Overview; Exhibits2: Executive Summary - Data Table on Market Overview; Exhibits3: Executive Summary - Chart on Country Market Characteristics; Exhibits4: Executive Summary - Chart on Market Segmentation by Route of Administration; Exhibits5: Executive Summary - Chart on Market Segmentation by Type; Exhibits6: Executive Summary - Chart on Company Market Positioning; Exhibits7: Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria; Exhibits8: Overview on criticality of inputs and factors of differentiation; Exhibits9: Overview on factors of disruption; Exhibits10: Impact of drivers and challenges in 2024 and 2029; Exhibits11: Parent Market; Exhibits12: Data Table on - Parent Market; Exhibits13: Market characteristics analysis; Exhibits14: Value chain analysis; Exhibits15: Offerings of companies included in the market definition; Exhibits16: Market segments; Exhibits17: Chart on US - Market size and forecast 2024-2029 ($ billion); Exhibits18: Data Table on US - Market size and forecast 2024-2029 ($ billion); Exhibits19: Chart on US: Year-over-year growth 2024-2029 (%); Exhibits20: Data Table on US: Year-over-year growth 2024-2029 (%); Exhibits21: Historic Market Size - Data Table on Multiple Sclerosis Market in US 2019 - 2023 ($ billion); Exhibits22: Historic Market Size - Route of Administration Segment 2019 - 2023 ($ billion); Exhibits23: Historic Market Size - Type Segment 2019 - 2023 ($ billion); Exhibits24: Five forces analysis - Comparison between 2024 and 2029; Exhibits25: Bargaining power of buyers - Impact of key factors 2024 and 2029; Exhibits26: Bargaining power of suppliers - Impact of key factors in 2024 and 2029; Exhibits27: Threat of new entrants - Impact of key factors in 2024 and 2029; Exhibits28: Threat of substitutes - Impact of key factors in 2024 and 2029; Exhibits29: Threat of rivalry - Impact of key factors in 2024 and 2029; Exhibits30: Chart on Market condition - Five forces 2024 and 2029; Exhibits31: Chart on Route of Administration - Market share 2024-2029 (%); Exhibits32: Data Table on Route of Administration - Market share 2024-2029 (%); Exhibits33: Chart on Comparison by Route of Administration; Exhibits34: Data Table on Comparison by Route of Administration; Exhibits35: Chart on Parenteral - Market size and forecast 2024-2029 ($ billion); Exhibits36: Data Table on Parenteral - Market size and forecast 2024-2029 ($ billion); Exhibits37: Chart on Parenteral - Year-over-year growth 2024-2029 (%); Exhibits38: Data Table on Parenteral - Year-over-year growth 2024-2029 (%); Exhibits39: Chart on Oral - Market size and forecast 2024-2029 ($ billion); Exhibits40: Data Table on Oral - Market size and forecast 2024-2029 ($ billion); Exhibits41: Chart on Oral - Year-over-year growth 2024-2029 (%); Exhibits42: Data Table on Oral - Year-over-year growth 2024-2029 (%); Exhibits43: Market opportunity by Route of Administration ($ billion); Exhibits44: Data Table on Market opportunity by Route of Administration ($ billion); Exhibits45: Chart on Type - Market share 2024-2029 (%); Exhibits46: Data Table on Type - Market share 2024-2029 (%); Exhibits47: Chart on Comparison by Type; Exhibits48: Data Table on Comparison by Type; Exhibits49: Chart on Biologics - Market size and forecast 2024-2029 ($ billion); Exhibits50: Data Table on Biologics - Market size and forecast 2024-2029 ($ billion); Exhibits51: Chart on Biologics - Year-over-year growth 2024-2029 (%); Exhibits52: Data Table on Biologics - Year-over-year growth 2024-2029 (%); Exhibits53: Chart on Small molecules - Market size and forecast 2024-2029 ($ billion); Exhibits54: Data Table on Small molecules - Market size and forecast 2024-2029 ($ billion); Exhibits55: Chart on Small molecules - Year-over-year growth 2024-2029 (%); Exhibits56: Data Table on Small molecules - Year-over-year growth 2024-2029 (%); Exhibits57: Market opportunity by Type ($ billion); Exhibits58: Data Table on Market opportunity by Type ($ billion); Exhibits59: Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria; Exhibits60: Impact of drivers and challenges in 2024 and 2029; Exhibits61: Overview on criticality of inputs and factors of differentiation; Exhibits62: Overview on factors of disruption; Exhibits63: Impact of key risks on business; Exhibits64: Companies covered; Exhibits65: Company ranking index; Exhibits66: Matrix on companies position and classification; Exhibits67: Bayer AG - Overview; Exhibits68: Bayer AG - Business segments; Exhibits69: Bayer AG - Key news; Exhibits70: Bayer AG - Key offerings; Exhibits71: Bayer AG - Segment focus; Exhibits72: SWOT; Exhibits73: Biogen Inc. - Overview; Exhibits74: Biogen Inc. - Product / Service; Exhibits75: Biogen Inc. - Key news; Exhibits76: Biogen Inc. - Key offerings; Exhibits77: SWOT; Exhibits78: Bristol Myers Squibb Co. - Overview; Exhibits79: Bristol Myers Squibb Co. - Product / Service; Exhibits80: Bristol Myers Squibb Co. - Key news; Exhibits81: Bristol Myers Squibb Co. - Key offerings; Exhibits82: SWOT; Exhibits83: F. Hoffmann La Roche Ltd. - Overview; Exhibits84: F. Hoffmann La Roche Ltd. - Business segments; Exhibits85: F. Hoffmann La Roche Ltd. - Key news; Exhibits86: F. Hoffmann La Roche Ltd. - Key offerings; Exhibits87: F. Hoffmann La Roche Ltd. - Segment focus; Exhibits88: SWOT; Exhibits89: Johnson and Johnson Inc. - Overview; Exhibits90: Johnson and Johnson Inc. - Business segments; Exhibits91: Johnson and Johnson Inc. - Key news; Exhibits92: Johnson and Johnson Inc. - Key offerings; Exhibits93: Johnson and Johnson Inc. - Segment focus; Exhibits94: SWOT; Exhibits95: Novartis AG - Overview; Exhibits96: Novartis AG - Business segments; Exhibits97: Novartis AG - Key news; Exhibits98: Novartis AG - Key offerings; Exhibits99: Novartis AG - Segment focus; Exhibits100: SWOT; Exhibits101: Pfizer Inc. - Overview; Exhibits102: Pfizer Inc. - Product / Service; Exhibits103: Pfizer Inc. - Key news; Exhibits104: Pfizer Inc. - Key offerings; Exhibits105: SWOT; Exhibits106: Sanofi SA - Overview; Exhibits107: Sanofi SA - Business segments; Exhibits108: Sanofi SA - Key news; Exhibits109: Sanofi SA - Key offerings; Exhibits110: Sanofi SA - Segment focus; Exhibits111: SWOT; Exhibits112: Teva Pharmaceutical Industries Ltd. - Overview; Exhibits113: Teva Pharmaceutical Industries Ltd. - Business segments; Exhibits114: Teva Pharmaceutical Industries Ltd. - Key news; Exhibits115: Teva Pharmaceutical Industries Ltd. - Key offerings; Exhibits116: Teva Pharmaceutical Industries Ltd. - Segment focus; Exhibits117: SWOT; Exhibits118: Viatris Inc. - Overview; Exhibits119: Viatris Inc. - Business segments; Exhibits120: Viatris Inc. - Key news; Exhibits121: Viatris Inc. - Key offerings; Exhibits122: Viatris Inc. - Segment focus; Exhibits123: SWOT; Exhibits124: Inclusions checklist; Exhibits125: Exclusions checklist; Exhibits126: Currency conversion rates for US$; Exhibits127: Research methodology; Exhibits128: Information sources; Exhibits129: Data validation; Exhibits130: Validation techniques employed for market sizing; Exhibits131: Data synthesis; Exhibits132: 360 degree market analysis; Exhibits133: List of abbreviations